ReviewCurrent opinion in immunology2025
Beyond skin deep: total-body positron emission tomography to illuminate systemic inflammation in psoriatic arthritis.
Review in Current opinion in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Psoriatic arthritis (PsA) is a systemic, immune-mediated disorder characterized by inflammation across peripheral and axial joints, entheses, skin, and nails. Given this heterogeneous manifestation, PsA presents unique challenges in clinical diagnosis and management. Conventional imaging, limited to localized, anatomical assessments, often fails to capture the full spectrum of PsA's systemic inflammatory burden, particularly subclinical disease. This review explores the emerging role of total-body positron emission tomography (TB-PET), offering a comprehensive assessment of molecular and metabolic processes across all affected tissues of the body in a single, short, low-dose scan. With PET radiotracers targeting glucose metabolism, T-cell trafficking, and macrophage activation, TB-PET may serve as a gateway to assess the spectrum and degree of inflammation in all the pathologic domains underlying PsA. Ultimately, by bridging molecular imaging with immunology and observable phenotypic features, TB-PET may open new avenues for understanding the pathophysiology of PsA, impacting both research paradigms and clinical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.